This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): Combivent Respimat, Combivent MDI, albuterol/ipratropium
Description: Combivent is a combination of the beta2-adrenergic bronchodilator albuterol and the anticholinergic ipratropium.
Combivent Inhalation Aerosol is approved for use with a metered-dose inhaler (MDI). Each actuation meters 21 mcg of ipratropium bromide and 120 mcg ofalbuterol sulfate from the valve and delivers 18 mcg of ipratropium bromide and 103 mcg of albuterolsulfate (equivalent to 90 mcg albuterol base) from the mouthpiece.
Combivent is also being developed for use with Respimat soft mist inhaler (SMI), delivering 20 mcg of ipratropium bromide and 100 mcg of albuterol sulfate.
Additional information available to subscribers only: